Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameFrontage
Stock Code01521
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們為合同研究機構,提供貫穿藥物發現和開發過程的一體化、科學驅動的研究、分析和開發服務,協助製藥公司實現藥物開發目標,於美國和中國均擁有業務。
Listing Date2019-05-30
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港銅鑼灣希慎道33號利園一期19樓1920室
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitefrontagelab.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 3.20 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1e-05 / shares
Offer Period2019-05-17 to 2019-05-22
Global Offering Shares501,910,000 shares
HK Public Offer Shares (Initial)50,192,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)451,718,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO2,007,640,910 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share41.5%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,606,112,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 2.68B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +250%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約11.24百萬美元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 134
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 201620172018
Revenue 48,64470,24583,114
Cost of sales -29,353-39,162-49,216
Gross profit 19,29131,08333,898
Other income and gains, net 312244467
Selling and distribution expenses -1,894-1,569-2,585
Administrative expenses -6,522-8,285-10,368
Operating profit 10,07417,79214,135
Net finance costs -272-315-378
Share of associates and JVs 568-1,345336
Profit before tax 10,37016,13214,093
Income tax expense -3,134-5,967-2,852
Profit for the year 6,64610,16511,241
Profit attributable to owners 6,64610,16511,241
Balance Sheet
Item 201620172018
Cash and cash equivalents 3,2544,33916,306
Trade and bills receivables 8,34413,16119,456
Inventories 0073
Total current assets 17,53830,33344,188
Total assets 42,63957,19177,464
Total current liabilities 15,76219,60229,734
Total liabilities 23,85826,97133,830
Total equity 18,78130,22043,634
Equity attributable to owners 18,78130,22043,634
Interest-bearing borrowings 7,73710,6708,842
Cash Flow Statement
Item 201620172018
Net cash from operating activities 9,3456,75922,658
Net cash from investing activities -7,392-7,038-11,435
Net cash from financing activities -2,1141,0681,329
Depreciation of PP&E 2,6683,0054,234
Amortisation of intangible assets 0075
Purchase of PP&E -4,019-3,215-5,220
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 3.35
First Day OpenHK$ 3.68
First Day Change4.69%
First Day Volume280684000.0
First Day Turnover1007630000.0
Use of Proceeds
1、預計于上市后12至18個月內將所分配金額約272百萬港元(或所得款項凈額的約20%)用于以下預期開支: (1)約81百萬港元的款項將用于改善、升級及擴大我們位于美國的現有設施; (2)約46百萬港元的款項將用于我們計劃于中國上海張江高科技園租賃的總建筑面積約為40,000至50,000平方呎的新設施的翻新; (3)約39百萬港元的款項將用于改善本集團于美國及中國運營的系統、流程及應用程式; (4)約106百萬港元的款項將用于為我們的設施購買新設備及技術,以及于美國及中國聘請更多科學家; 2、約545百萬港元的款項(或所得款項凈額的約40%)于上市后12至18個月內將用于有機地擴大及拓寬我們的能力及服務范圍; 3、約408百萬港元的款項(或所得款項凈額的約30%)將用于通過潛在收購; 4、約136百萬港元的款項(或所得款項凈額的約10%)將用作為營運資金及一般企業用途,包括(尤其是)改善我們業務的常規制度、經營及流程。

Underwriting Syndicate

Joint Sponsors (2)
Merrill Lynch (Asia Pacific) Limited CE AAC198 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中信里昂证券有限公司 CE AAB893 海通国际证券有限公司 CE AAF806
Joint Bookrunners (4)
Merrill Lynch (Asia Pacific) Limited CE AAC198 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中信里昂证券有限公司 CE AAB893 海通国际证券有限公司 CE AAF806

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Hillhouse Funds 392,422,400 HKD — 24.40% — 6 months 2019-11-30
2 Worldwide Healthcare Trust PLC 117,721,600 HKD — 7.30% — 6 months 2019-11-30
3 景林资产管理有限公司 156,966,400 HKD — 9.80% — 6 months 2019-11-30

Directors & Management

PositionChinese nameEnglish Name
Chairman李志和—
Company Secretary張盈倫—
No director data available.

Major Shareholders

Major Shareholders & Holdings香港泰格及杭州泰格為控股股東,緊隨全球發售及資本化發行完成後持股51.45%;李松博士持股9.60%;Hillhouse Capital Advisors, Ltd.持股7.77%;Gaoling Fund, L.P.持股7.20%。
About this page

This page shows Frontage (01521) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect